Autoimmune diseases are not a single therapeutic area, but rather a spectrum of indications with overlapping mechanisms. Rheumatoid arthritis, psoriasis, systemic lupus erythematosus, multiple sclerosis, Crohn’s disease, ulcerative colitis and other inflammatory diseases frequently share molecular targets, raising the question of which indication to pursue first. Development plans must account not only for mechanistic fit, but also market size and pricing strategy. The challenge is to adopt a planning process that leverages core skills and assets across therapeutic category boundaries in order to fully realize a candidate’s commercial potential.

Indications in which Health Advances has expertise include:
  • Crohn’s disease
  • Inflammatory bowel disease
  • Multiple sclerosis
  • Neuromyelitis optica
  • Psoriasis
  • Rheumatoid arthritis
  • Scleroderma
  • Sjogren’s syndrome
  • Systemic lupus erythematosus
  • Type 1 diabetes
  • Ulcerative colitis
  • Vitiligo

View our Autoimmune Diseases case examples.

See an example of a client case on clinical development strategy for inflammatory bowel disease.